COVID-19: Seeking distributors for an accurate and sensitive PCR test for the detection of SARS-CoV-2

The UK company provides simple, reliable and effective solutions to aid the accurate diagnosis of diseases and improvement of patient management. All the products are designed and produced to work on the most commercially available detection systems to enable a rapid introduction into molecular diagnostics laboratories. They have developed a strong IP portfolio including three patent protected PCR-based technologies that have modernised molecular diagnostics in the fields of infectious disease (papilloma, respiratory), cancer (liquid biopsy via circulating tumour DNA), and personalised medicine (right drugs for best outcome). Their molecular diagnostic solutions are supplied to several countries (China, France, Czech Republic, Mexico, Malaysia and parts of the Middle East). The company has developed a CE-IVD solution based on RT-qPCR technology for the detection of COVID-19 (COVID-19 detection kit) that has been independently validated by PHE (Public Health England) and FIND (Foundation for Innovative New Diagnostics, Switzerland). Their kit has been designed to detect two RNA targets of SARS-CoV2 (ORF1ab and N gene) as well as an endogenous human gene for sample integrity and PCR controls. The limit of detection is between 10 and 100 copies per reactions and specificity between 99 and 100%. The company have already found distributors in France and the Czech Republic and are seeking new partners for their kit, from companies or government agencies seeking fast and reliable tests for the presence of Covid-19 infection, via distribution agreement.